Technical Analysis for MLTX - MoonLake Immunotherapeutics
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Up | Flat | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| 50 DMA Resistance | Bearish | 0.18% | |
| MACD Bearish Signal Line Cross | Bearish | 0.18% | |
| 20 DMA Support | Bullish | 0.18% | |
| Multiple of Ten Bearish | Other | 0.18% | |
| Crossed Above 20 DMA | Bullish | 1.18% | |
| NR7 | Range Contraction | 1.18% | |
| NR7-2 | Range Contraction | 1.18% | |
| 20 DMA Resistance | Bearish | 2.82% | |
| NR7 | Range Contraction | 2.82% | |
| Fell Below 20 DMA | Bearish | 2.21% |
| Alert | Time |
|---|---|
| 20 DMA Support | about 1 hour ago |
| Outside Day | about 2 hours ago |
| Fell Below Previous Day's Low | about 2 hours ago |
| Down 1% | about 2 hours ago |
| 50 DMA Resistance | about 2 hours ago |
Get this analysis on your stocks daily!
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 11/12/2024
MoonLake Immunotherapeutics is a clinical-stage biopharmaceutical company unlocking the potential of sonelokimab, the first investigational Nanobody® for the treatment of inflammation, to revolutionize outcomes for patients. Sonelokimab optimally inhibits IL-17A and IL-17F inhibition to treat inflammatory diseases, by independently inhibiting the naturally-occurring IL-17 A/A, A/F and F/F dimers that drive inflammation in patients. The Company’s focus is on inflammatory diseases with a major unmet need with lead indications currently progressing into Phase 2 trials for hidradenitis suppurativa, psoriatic arthritis, ankylosing spondylitis or radiographic axial spondyloarthritis. MoonLake is headquartered in Zug, Switzerland.
Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Clinical Medicine Organ Systems Autoimmune Disease Inflammation Inflammatory Diseases Arthritis Rheumatology Psoriatic Arthritis Hidradenitis Suppurativa Interleukin 17 Interleukins Spondylitis
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Clinical Medicine Organ Systems Autoimmune Disease Inflammation Inflammatory Diseases Arthritis Rheumatology Psoriatic Arthritis Hidradenitis Suppurativa Interleukin 17 Interleukins Spondylitis
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 64.98 |
| 52 Week Low | 37.55 |
| Average Volume | 339,104 |
| 200-Day Moving Average | 46.90 |
| 50-Day Moving Average | 50.03 |
| 20-Day Moving Average | 49.16 |
| 10-Day Moving Average | 50.83 |
| Average True Range | 2.31 |
| RSI (14) | 50.74 |
| ADX | 14.97 |
| +DI | 23.39 |
| -DI | 19.31 |
| Chandelier Exit (Long, 3 ATRs) | 47.89 |
| Chandelier Exit (Short, 3 ATRs) | 52.16 |
| Upper Bollinger Bands | 53.74 |
| Lower Bollinger Band | 44.58 |
| Percent B (%b) | 0.57 |
| BandWidth | 18.64 |
| MACD Line | 0.32 |
| MACD Signal Line | 0.35 |
| MACD Histogram | -0.0264 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 52.84 | ||||
| Resistance 3 (R3) | 52.89 | 51.93 | 52.33 | ||
| Resistance 2 (R2) | 51.93 | 51.17 | 51.91 | 52.16 | |
| Resistance 1 (R1) | 50.88 | 50.69 | 51.41 | 50.83 | 52.00 |
| Pivot Point | 49.92 | 49.92 | 50.19 | 49.90 | 49.92 |
| Support 1 (S1) | 48.87 | 49.16 | 49.40 | 48.82 | 47.64 |
| Support 2 (S2) | 47.91 | 48.68 | 47.89 | 47.48 | |
| Support 3 (S3) | 46.86 | 47.91 | 47.31 | ||
| Support 4 (S4) | 46.81 |
